R. Furie, Sander W Tas, Ana Malvar, Cary M Looney, Harini Raghu, Veronica G Anania, Ashley Mao, Thomas Schindler, Elsa Martins, Jorge A Ross Terres, Edward M Vital
{"title":"O33 NOBILITY中生物标志物的纵向评估,NOBILITY是奥比妥珠单抗治疗增生性狼疮肾炎的随机II期临床试验","authors":"R. Furie, Sander W Tas, Ana Malvar, Cary M Looney, Harini Raghu, Veronica G Anania, Ashley Mao, Thomas Schindler, Elsa Martins, Jorge A Ross Terres, Edward M Vital","doi":"10.1136/lupus-2024-el.42","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517941,"journal":{"name":"Oral Presentations","volume":"57 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis\",\"authors\":\"R. Furie, Sander W Tas, Ana Malvar, Cary M Looney, Harini Raghu, Veronica G Anania, Ashley Mao, Thomas Schindler, Elsa Martins, Jorge A Ross Terres, Edward M Vital\",\"doi\":\"10.1136/lupus-2024-el.42\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517941,\"journal\":{\"name\":\"Oral Presentations\",\"volume\":\"57 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Presentations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2024-el.42\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Presentations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2024-el.42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis